Chief Executive Officer:
Constantinos Evripides

Number of employees: (12/2020) :

Turnover (2019):
€122.75 million

Awards: CR Index 2019-2020 (Platinum Award & Best Progress Award), Best Workplaces (2018-2019, 19 national and European distinctions since 2003), The Most Sustainable Companies in Greece 2020/QualityΝet Foundation, Growth Awards “Corporate Social Responsibility” 2018

The leading Greek pharmaceutical company GENESIS Pharma was founded with a mission to address unmet patient needs through innovation. It was one of the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products and is currently the largest by turnover among Greek companies focusing on innovative medicines.

Through long-standing strategic partnerships with some of the leading global pharmaceutical companies committed to cutting-edge R&D, GENESIS Pharma has created a strong portfolio of innovative and high therapeutic value pharmaceutical products for more than 30 severe and rare diseases.

It is acknowledged as one of the most specialized companies in multiple sclerosis in Greece with an extensive product portfolio for the disease and an expertise of more than 20 years, as it exclusively represents Biogen, a leading company in multiple sclerosis and neuroscience research worldwide. In addition, its significant activity in biotechnology has expanded in recent years in the field of biosimilar medicines, with a biosimilars portfolio of advanced biologics for a range of rheumatological, dermatological and gastrointestinal chronic inflammatory diseases.

Its portfolio also includes pioneering treatments for rare genetic diseases. Amongst these, the first drug therapy approved for the treatment of spinal muscular atrophy (SMA) with unsurpassed real-world experience and a robust level of clinical evidence, the first oral treatment coming from research in precision medicine for Fabry disease, as well as a first-in-class RNAi therapeutic based on Nobel Prize-winning science for hATTR amyloidosis. Finally, the company has a wide range of innovative medicines for rare hematological malignancies, including multiple myeloma, types of leukemia and lymphomas, as well as myelodysplastic syndromes.

GENESIS Pharma is one of the most awarded companies in the country for its commitment to sustainable development and good working environment, with a yearly contribution to the Greek economy and society that exceeds 30% of its annual turnover.

270, Kifissias Av., 152 32 Halandri Greece

+30 (210) 87 71 500

+30 (210) 68 93 877


[email protected]

Biogen International GMBH, Celgene Logistic SARL, PharmaMar S.A., Incyte Biosciences International SA, Amicus Therapeutics Europe Limited, Alnylam Pharmaceuticals Switzerland GmbH, VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA, Vifor Pharma Inc., Takeda France SAS